Embolx products enable breakthrough improvements in cancer therapy.
Embolx develops transarterial delivery systems for super-selective cancer therapy that enable physicians to deliver anticancer agents directly into the tumor vasculature. Uniquely, Embolx devices use pressure regulation to eliminate non-target delivery & increase drug distribution in the tumor. In the US & EU, 1.5M cases are amenable to this therapy. The company expects revenues in Q1 2015 & to be CF positive on <$5M total paid-in capital.